Results Highlights for Interim Results ended 30 June 2025 Revenue reached RMB831.9 million Gross profit amounted to RMB339.4 million Gross profit margin was 40.8%, an increase of 6.3 percentage point Net profit amounted to RMB148.6 million, increased by 3.1% YoY Adjusted non-IFRS net...
Hence then, the article about viva biotech announces its 2025 interim results cro revenue returned to positive growth new cdmo commercialization projects showed promising growth was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth )
Also on site :
- Seizure of Russian-flagged oil tanker: what we know so far
- 'TV star Nick Owen recovering from second cancer scare - Midlands Today presenter reveals he has had surgery for disease in his kidney
- Fatal I-55 crash shuts down lanes in southwest suburbs; ‘major' traffic backups expected